Albireo Pharma Inc logo

ALBO

Albireo Pharma Inc

$17.01

Earnings Summary

Revenue
$6.83Mn
Net Profits
$-42.43Mn
Net Profit Margins
-621.11%

Highlights

Revenue:

Albireo Pharma Inc’s revenue jumped 247.51% since last year same period to $6.83Mn in the Q1 2022. On a quarterly growth basis, Albireo Pharma Inc has generated -78.99% fall in its revenue since last 3-months.

Net Profits:

Albireo Pharma Inc’s net profit jumped 2.97% since last year same period to $-42.43Mn in the Q1 2022. On a quarterly growth basis, Albireo Pharma Inc has generated -287.1% fall in its net profits since last 3-months.

Net Profit Margins:

Albireo Pharma Inc’s net profit margin jumped 72.08% since last year same period to -621.11% in the Q1 2022. On a quarterly growth basis, Albireo Pharma Inc has generated -1742.64% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Albireo Pharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.65
EPS Estimate Current Year
-1.65

Highlights

EPS Estimate Current Quarter:

Albireo Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -1.65 - a 10.81% jump from last quarter’s estimates.

EPS Estimate Current Year:

Albireo Pharma Inc’s earning per share (EPS) estimates for the current year stand at -1.65.

Key Ratios

Key ratios of the Albireo Pharma Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-2.19
Return on Assets (ROA)
-0.3
Return on Equity (ROE)
-0.22
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Albireo Pharma Inc’s earning per share (EPS) jumped 4.37% since last year same period to -2.19 in the Q1 2022. This indicates that the Albireo Pharma Inc has generated 4.37% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Albireo Pharma Inc’s return on assets (ROA) stands at -0.3.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Albireo Pharma Inc’s return on equity (ROE) stands at -0.22.

Dividend Per Share (DPS):

Albireo Pharma Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-1.85
-2.19
-18.38%

Company Information

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Organisation
Albireo Pharma Inc
Headquarters
10 Post Office Square, Boston, MA, United States, 02109
Employees
90
Industry
Health Technology
CEO
Gary Gemignani